In summary, this study demonstrated that APN deficiency could promote CD8+ T cell activation and their cytotoxicity to kill tumors via inhibiting the STAT3 signaling pathway, and proved that targeting APN had potential in the treatment of rhabdomyosarcoma. This evidence concerns the gene CD8A and rhabdomyosarcoma.